Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Embracing the Challenge and the Grind: Paul G. Richardson is a Giant of Cancer Care in Myeloma

March 23rd 2022

Paul G. Richardson, MD, started his journey in medicine delivering tea and biscuits to patients and ended up making seminal advances in myeloma care.

Cilta-cel Offers Durable Option for Heavily Pretreated Multiple Myeloma

March 23rd 2022

The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma, following 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

CD34 Selection Process Evolves into Practice-Changing Approaches in Hematologic Cancers

March 21st 2022

Miguel-Angel Perales, MD, discusses the science behind Orca-T and other approaches targeted to improve GVHD relapse-free survival in select patients with hematologic cancers.

Dr. Abid on the Efficacy of a Third COVID-19 Vaccine Dose After Hematopoietic Cell

March 17th 2022

Muhammad Bilal Abid, MD, MRCP, discusses the efficacy of a third COVID-19 vaccine dose after hematopoietic cell transplantation in patients with hematologic malignances.

Lyle and Patel Examine Diagnostic and Management Paradigms in MDS

March 17th 2022

Drs Lyle and Patel review some of the challenges associated with the diagnosis and management of myelodysplastic syndromes, the current treatment landscape, and the role of next-generation sequencing and optimal testing practices in the field.

New Approvals Heighten Expectations Throughout Hematologic Malignancies

March 17th 2022

Haris Ali, MD, discusses updates in acute and chronic graft-vs-host-disease, current and emerging agents in myelofibrosis and polycythemia vera, and chronic lymphocytic leukemia management.

Empathy Matters Most: Steven T. Rosen Is a Giant of Cancer Care in Lymphoma

March 17th 2022

“I still have about 250 active patients with blood cancers, and every single one has my cell phone. I do everything in real time....That connection is very important and meaningful for me.”

FDA Grants Orphan Drug Designation to TCB-002 for Relapsed/Refractory AML

March 17th 2022

The FDA has granted an orphan drug designation to the investigative allogeneic unmodified gamma delta T-cell product, TCB-002, for use as a potential therapeutic option in patients with relapsed/refractory acute myeloid leukemia.

Uproleselan Plus Chemotherapy Continues to Show Promise in AML

March 17th 2022

The addition of uproleselan to standard chemotherapy improved improve response rates and reduced chemotherapy-induced mucositis in patients with newly diagnosed and relapsed/refractory acute myeloid leukemia in a phase 1/2 trial.

Dr. Sallman on the Role of Uproleselan in Targeting E-Selectin in AML

March 16th 2022

David Sallman, MD, discusses the role of uproleselan (GMI-1271) when utilized in acute myeloid leukemia.

Unmet Needs in the Management of Multiple Myeloma

March 11th 2022

Sagar Lonial, MD, provides insight on mechanisms of resistance to CAR T-cell therapies, and the panel shares unmet needs and future directions for the treatment of multiple myeloma.

Seeing Cancer From All Sides: Richard M. Stone Is Giant of Cancer Care in Leukemia

March 11th 2022

Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research.

Role of CAR T Therapies in Newly Diagnosed Multiple Myeloma

March 11th 2022

Ola Landgren, MD, PhD, leads the discussion on the use of cilta-cel and ide-cel in newly diagnosed multiple myeloma and the sequencing of available therapies in transplant-eligible and transplant-ineligible patients.

Novel CAR-T Therapies in Relapsed/Refractory MM and Identifying the Right Patients for CAR-T Therapies

March 11th 2022

Experts discuss emerging BCMA-targeting CAR T-cell therapies under investigation for treating multiple myeloma and barriers to CAR T access.

FDA Places Partial Clinical Hold on NEON-2 Trial Evaluating Davoceticept/Pembrolizumab in Advanced Cancers

March 8th 2022

The FDA has placed a partial clinical hold on the phase 1 NEON-2 trial examining the combination of davoceticept and pembrolizumab in patients with advanced solid tumors or lymphoma.

FDA Grants Priority Review to Ivosidenib Plus Azacitidine for Previously Untreated IDH1-Mutated AML

March 7th 2022

The FDA has granted priority review to a supplemental new drug application seeking the approval of ivosidenib in combination with azacitidine in the treatment of patients with previously untreated IDH1-mutated acute myeloid leukemia.

KarMMa Study in Relapsed/Refractory Multiple Myeloma

March 4th 2022

Katja Weisel, MD, reviews the study results from the KarMMa study evaluating the use of ide-cel in patients with relapsed/refractory multiple myeloma.

CARTITUDE-1 Study in Relapsed/Refractory Multiple Myeloma

March 4th 2022

Ola Landgren, MD, PhD, leads a review of the updated efficacy and safety results and subgroup analysis of the CARTITUDE-1 study for patients with relapsed/refractory multiple myeloma.

Investigators Push to Leverage Liquid Biopsy As New Standard in Early Detection, Prognosis of Hematologic Malignancies

March 3rd 2022

Leveraging the advances made with liquid biopsies in pantumor assays and specific hematologic cancers has laid the groundwork for the shift in care by using single, or multifaceted approaches for identifying, predicting, and monitoring disease progression.

Future Management of Chronic Myeloid Leukemia

March 2nd 2022

Closing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.